Data from LAG-3 trials caused a stir at the 2021 ASCO meeting, with promising clinical data in this third class of checkpoint inhibitor presented by firms such as Regeneron Pharmaceuticals, Inc., Merck & Co., Inc. and – with a different approach - Immutep Ltd. (Also see "ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations" - Scrip, 7 June, 2021.)
In the year since, the FDA has approved Bristol Myers Squibb Company’s LAG-3 blocker relatlimab in a fixed-dose combination...